Cargando…
Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?
Immune checkpoint inhibitors (ICIs) have significantly improved the outcome of patients with metastatic urothelial cancer (mUC). If these agents were first used in monotherapy after failure of platinum-based chemotherapy, new strategies have been evaluated in the last years, including association of...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917314/ https://www.ncbi.nlm.nih.gov/pubmed/35278793 http://dx.doi.org/10.1016/j.tranon.2022.101387 |